EGFR Biomarkers News and reporting on EGFR biomarkers. Nov 10, 2022 AstraZeneca Q3 Revenues From Oncology Products Grow 20 Percent Premium Oct 18, 2022 Ikena Oncology to Study IK-930, Tagrisso Combo in EGFR-Mutant NSCLC Oct 3, 2022 Theseus Pharmaceuticals to Develop Pan-EGFR Inhibitor for Resistant NSCLC Patients Sep 11, 2022 Repeat Biomarker Testing Informs Next Steps for Treatment-Resistant EGFR-Mutant NSCLC Patients Premium Sep 11, 2022 ESMO Study Explores Role of Air Pollution in EGFR-Mutant NSCLC in Non-Smokers Premium Aug 29, 2022 RedCloud Begins Phase I/IIa Trial in EGFR TKI-Resistant Lung Cancer Aug 25, 2022 AstraZeneca's Tagrisso, Lynparza Net Adjuvant Approvals in Japan Aug 11, 2022 New Drugs Going After 'Achilles' Heel' Resistance Mutation in NSCLC Premium Jul 29, 2022 AstraZeneca Q2 Oncology Sales Grow 14 Percent as Firm Awaits Key Precision Drug Regulatory Decisions Premium Jul 28, 2022 EGFR Exon 20 Insertion Location Could Be Key Factor in NSCLC Treatment Premium Jul 14, 2022 Lantern Pharma Gets FDA Nod to Begin Phase II Trial of LP-300 in Biomarker-Defined NSCLC Jul 8, 2022 Mass General Program to Help Doctors Balance End-of-Life Talks With Precision Oncology Optimism Premium Jun 27, 2022 Alaunos, NCI Expand Partnership to Explore Personalized Autologous T-Cell Therapy Jun 4, 2022 Drugmakers Push to Improve Treatment in Key NSCLC Subgroups, Find Options Where There Are Few May 12, 2022 Taiho Pharmaceutical Acquires Cullinan Pearl, Regaining Rights to EGFR Inhibitor May 9, 2022 Theseus Pharmaceuticals Addressing KIT, EGFR Resistance With Pan-Variant Inhibitors Premium May 2, 2022 Alaunos Therapeutics Begins Study of Autologous Cell Therapy Using Non-Viral Gene Transfer Apr 29, 2022 AstraZeneca Q1 Oncology Product Sales Increase 14 Percent Led by Tagrisso Apr 26, 2022 Black Diamond Therapeutics to Discontinue ErbB Inhibitor Program, Lay Off 30 Percent of Workforce Apr 18, 2022 Black Diamond Therapeutics Doses First Patient in Recurrent EGFR-Mutant Glioblastoma, NSCLC Trial Load More Breaking News Apollomics Completes SPAC Merger, Begins Public Trading on Nasdaq Ablaze Pharmaceuticals to Develop RayzeBio's GPC3-Targeted Radiotherapy In Brief This Week: Allarity Therapeutics, Immutep, Thermo Fisher Scientific EMA's CHMP Recommends BMS's Breyanzi as Second-Line Lymphoma Treatment Exai Bio, Quantum Leap Healthcare Collaborative Expand Participation in RNA Liquid Biopsy Trial Omega Therapeutics, Roche Partner for Phase I/II Trial in MYC-Driven Hepatocellular Carcinoma
